

TUBERCULOSIS 2001

Cases = 115

Crude Incidence Rate per 100,000 population = 1.9

Race and Ethnicity-specific Incidence Rates per 100,000 population

White, non-Hispanic = 1.0

Black, non-Hispanic = 5.9

Hispanic, all races = 7.9

Asian or Pacific Islander= 24.5

Gender-specific Incidence Rates per 100,000 population

Male = 2.5

Female = 1.3

Tuberculosis (TB) is an airborne disease caused by a group of bacteria which is collectively referred to as *Mycobacterium tuberculosis* complex. The three species in this complex that cause disease in humans are *M. tuberculosis*, *M. bovis*, and *M. africanum*. General symptoms include a prolonged, productive cough, blood-tinged sputum, night sweats, fever, fatigue, and weight loss. TB usually affects the lungs, but can also affect other parts of the body like the brain, kidneys, or spine. TB bacilli are aerosolized when a person who has TB of the lungs or larynx coughs, sneezes, laughs, or sings. The droplet nuclei that are formed are inhaled by another person. Individuals who become infected but do not become ill are considered to have latent TB infection (LTBI) and cannot transmit the infection to others. Approximately 10% of infected individuals will progress to active disease at some point in their lives.

During 2001, 115 new cases of tuberculosis were reported to the Indiana State Department of Health (ISDH). Figures 1a. and 1b. show long-term and 5-year trends, respectively. New cases decreased by 20% from 2000. The state case rate was 1.9 cases per 100,000 population. TB was reported by 33 (36%) of the 92 counties. Five of the six most populous counties accounted for 60% of all cases.

Although the use of anti-TB chemotherapy has led to a tremendous decline in the number of new cases, deaths still occur from the disease. During 1997-2001, an average of 18 people died with TB each year in Indiana. Eight patients were dead at the time of diagnosis in 2001. A post-mortem diagnosis of TB suggests that there was either a delay in the patient seeking treatment or a failure to diagnose TB after the patient presented for treatment. Disease transmission is likely to have occurred during this time because these patients have been infectious for a much longer period of time than those who were alive at the time of diagnosis.

The number of TB-related deaths is shown in Figure 2. Patients who died after sputum culture conversion to negative, and those who demonstrated significant clinical improvement but died from other primary causes were excluded.

Figure 1a.




Figure 1b.





Figure 2.




A diagnosis of TB is verified using the Centers for Disease Control and Prevention's (CDC) "Case Definitions for Infectious Conditions Under Public Health Surveillance." TB cases must meet the case definition for either a laboratory or a clinical diagnosis. A laboratory diagnosis is confirmed when *M. tuberculosis* complex has been: 1) isolated from a culture or has been demonstrated in a clinical specimen by a nucleic acid amplification (NAA) test approved by the FDA, or 2) acid fast bacilli (AFB) are seen when a culture has not or cannot be obtained (usually used only to aid in a post-mortem diagnosis).

A clinical diagnosis is confirmed when all of the following criteria are met following a completed medical evaluation: a positive tuberculin skin test, other signs and symptoms compatible with current TB disease (e.g., an abnormal, unstable chest x-ray, night sweats, weight loss), and treatment with two or more anti-TB drugs. This category includes culture-negative pulmonary TB, extra-pulmonary TB where cultures would not grow or were not obtained, and children in whom obtaining specimens is difficult and invasive procedures are not warranted. Figure 3 shows the percentage of reported TB cases by case definition.

Figure 3.


TB Classification by Case Definition Indiana, 1997-2001



ISDH Tuberculosis Program

In 2001, males made up 65.2% and females made up 34.8%, respectively, of all newly diagnosed TB cases. Percentages of new cases by race and ethnicity are as follows: white, non-Hispanic (46.1%), black, non-Hispanic (26.1%), Hispanic, all races (14.8%), and Asian or Pacific Islander (13%). Figure 4 shows case rates per 100,000 population by race, ethnicity, and sex.


Figure 4.



ISDH Tuberculosis Program

Immigrants from high-prevalence countries continue to make up an increasingly larger proportion of TB cases. In 2001, 37% (42/115) of TB patients immigrated from countries with a high burden of TB (Figure 5). Immigrants from Latin America and the Caribbean accounted for 38.1% (16/42) of the cases, with 12 persons coming from Mexico. Asia accounted for 35.7% (15/42) of the foreign-born cases; Africa accounted for 16.7% (7/42); Europe accounted for 9.5% (4/42).


Figure 5.



ISDH Tuberculosis Program

This year, the over-65 age group no longer made up the largest percentage of TB cases. Case rates by age group are shown in figure 6. In 2001, 26.1% of the cases occurred in those who were over age 65, with a case rate of 4.0 per 100,000; 28.7% were age 45-64 with a case rate of 2.5. The age group of 25-44 represented the largest percentage of cases at 34.8% and a case rate of 2.2. The 15-24 age group made up 7.8% of all cases, with a case rate of 1.0. This year, 2.6% were under the age of 14 for a case rate of 0.2.


Figure 6.



ISDH Tuberculosis Program


Three children under the age of 15 were diagnosed in 2001 (Figure 7). Two children were four years of age. TB in young children represents recent transmission, usually from an adult household contact.

Figure 7.



HIV disease is the most significant risk factor for progression to active disease. In 2001, there were five individuals diagnosed with both TB and HIV (Figure 8). HIV status was known for 42% of the cases. HIV testing was not offered for 45% of the patients, while 13% refused to be tested. Current guidelines recommend HIV counseling and testing for all patients with TB.

Figure 8.



Other risk factors associated with TB exposure or progression to active disease are excess alcohol use, homelessness, illicit drug use (injecting and non-injecting), residence or employment in a high-risk congregate setting, or employment as a health care worker (HCW) serving high-risk clients. The numbers of persons reported with these risk factors are shown in Table 1.

Table 1.
Number of Reported Tuberculosis Cases
with Selected Exposure and Medical Risk Factors, 2001 (n=115)

Risk Factor	Yes (%)	No (%)
Excess alcohol use	22 (19)	93 (81)
Injection drug use	6 (5)	109 (95)
Non-injection drug use	4 (3)	111 (97)
Homelessness	4 (3)	111 (97)
LTC resident	3 (3)	112 (97)
Health care worker	NA	NA
Prison/Jail employee	NA	NA
Prison inmate	1 (1)	114 (99)

Occupation is another variable used to detect trends. Compilation of these data show that 47% of the individuals diagnosed with TB disease were unemployed and 53% had known employment (Table 2). The unemployed category includes retired persons, children, and students.


Table 2.
Number of Reported Tuberculosis Cases
by Selected Occupations, 2001 (n=115)

Occupation	Number of Cases	Percent of Cases
Unemployed	54	47%
Other occupations	60	52%
Unknown	0	0%
Migrant agricultural worker	1	1%
Health care worker	0	0%
Corrections worker	0	0%

Of the 115 cases reported in 2001, 69.6% (80/115) were exclusively pulmonary. Another 6.1% (7/115) were both pulmonary and extra-pulmonary. Pulmonary cases are the main public health concern since these individuals transmit the disease to others. To break this cycle of transmission, appropriate therapy must be initiated and continued for the duration of the treatment period. ISDH recommends and supports the treatment guidelines set by the American Thoracic Society and the Centers for Disease Control and Prevention (ATS/CDC). Since 1991, these guidelines have recommended that four drugs be used in the initial regimen. Figure 9 shows the impact of those guidelines on the prescribing practices of physicians.

In 2001, 75% (80/107) of the patients alive at the time of diagnosis began therapy on the preferred regimen containing isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA), with either ethambutol (EMB) or streptomycin (SM) included until drug susceptibility results were available. The percentage of patients who were started on at least INH, RIF, and PZA was 20% (21/107).

Figure 9.



ISDH Tuberculosis Program

Drug susceptibility testing was performed for all 93 cases with positive cultures. Of these, 3.2% (3/93) were resistant to INH. Multi-drug resistant (MDR) TB is defined as resistance to both INH and RIF. MDR-TB is of particular public health concern since these two drugs are the most effective. If the organism is resistant to them, less effective second-line drugs must be added, with the treatment period having to be extended from the usual 6-9 months to 18-24 months. There were no cases of MDR-TB reported for Indiana residents in 2001, although there was one imported case that was reported in another state.

INH-resistant TB is treatable and curable with the remaining three first-line drugs. Close and careful monitoring of these patients is necessary to prevent additional drug resistance. The number of drug resistant cases is shown in Figure 10.

TB Cases with Drug Resistance

Indiana, 1997-2001





Figure 10.

Besides drug resistance, inadequate response to therapy and non-compliance are major reasons for having to extend the treatment period. Sputum culture conversion data are collected to measure response to therapy and to identify reasons for the absence of documentation. The absence of documentation of culture conversion is most commonly due to inadequate patient follow-up and is addressed with the local health departments. Patients whose cultures have not become negative or whose symptoms have not improved after two months of therapy should be re-evaluated for drug resistance, as well as failing to adhere to the treatment regimen if they are not on directly observed therapy. The proportion of patients who convert their sputum cultures to negative within 60 days is shown in Figure 11.

Directly observed therapy (DOT) is the most effective method to assure that the patient is complying with the prescribed treatment regimen. DOT is a strategy proven to ensure completion of therapy, with the added benefit of preventing acquired drug resistance. DOT is the best practice and the standard of care in Indiana and should be used for all patients. Every effort must be made to initiate DOT when the patient is first started on anti-TB medications. Cohort year 2000 is the most recent period with complete DOT data. Eighty percent (111/138 alive at the time of diagnosis) of all patients that year were on DOT for at least some portion of the treatment period (Figure 12).

Figure 11.


Sputum Culture Conversion*, 2000



*sputum culture-positive patients alive at the time of diagnosis who began treatment;

ISDH Tuberculosis Program

Figure 12.



ISDH Tuberculosis Program


The first priority of TB control and prevention efforts is to ensure completion of therapy. Indiana's goal is to have at least 90% of all patients complete treatment within one year. The completion of therapy index is based on the number of patients for whom treatment for one year or less is indicated. Exclusions from the rate calculations are those who were dead at the time of diagnosis, patients who died before completing therapy, patients who were never started on therapy, and patients with multi-drug resistant disease. Therapy is considered to be incomplete for those patients who were reported as moved, uncooperative or refused, or lost to follow-up.

The current data are for those patients in cohort year 2000. The completion rate for that year was 88%, as shown in Figure 13. Data are not complete for those who took longer than one year to finish treatment, due to (1) disease relapses occurring less than one year after being discharged from medical supervision; (2) treatment failure; (3) medical complications with chemotherapy; and (4) non-compliance.

Figure 13.

Completion of Therapy

Indiana, 1996-2000



ISDH Tuberculosis Program (Total completing therapy n/a for 2000)

The second priority in TB control and prevention is to identify close contacts to patients with active pulmonary or laryngeal TB, and to encourage treatment for those who are infected. People in this group are at a much higher risk of progressing to active disease than those with latent TB infection (LTBI) who were not close contacts. Contact investigations should be initiated within three working days for sputum smear-positive cases that have a high degree of suspicion for TB. Contact investigations must be performed for all cases of laryngeal and sputum culture-positive pulmonary TB. Persons in the following categories who have LTBI are also at high risk for developing active disease once infected and should be treated regardless of their age: 1) individuals who have been infected within the last two years; 2) injection drug users; 3) persons known or suspected of having HIV infection; 4) persons with certain other medical conditions; 5) persons with a chest x-ray suggestive of previous TB who received inadequate treatment or were not treated; and 6) persons from countries where TB is common.

INH for nine months is the preferred course of treatment for LTBI, regardless of age or HIV status. INH for six months is an acceptable alternative if nine months of treatment is not possible. RIF for 4 months and RIF and PZA for two months are alternate regimens. RIF/PZA regimens should be used with caution and only in circumstances where the preferred regimen is not feasible. Completion of treatment data for infected

contacts is for cohort year 2000, and is shown in figure 14.

Figure 14.




Figure 15 shows the counties that reported 5 or more cases in 2001. The total number for the state is based on persons who had an Indiana address at the time of diagnosis and who were verified as having TB disease in 2001. Persons counted in another state and immigrants and refugees who are diagnosed and begin treatment abroad are excluded. Foreign visitors diagnosed in Indiana but who remain in the U.S. for less than 90 days of treatment are also excluded. There were 15 of these “not counted” cases in 2001.

